Enovis (ENOV) to Release Quarterly Earnings on Thursday

Key Points

• Enovis is scheduled to release its Q2 2025 earnings on August 7th, with analysts expecting $0.74 per share in earnings and $555.80 million in revenue.
• The company reported a positive earnings surprise in its last earnings release, posting $0.81 EPS against a consensus estimate of $0.74, along with revenue growth of 8.2% year-over-year.
• Institutional investors hold 98.45% of Enovis's stock, with significant increases in stakes from firms like Goldman Sachs, which boosted its position by 37.6% recently.

Enovis (NYSE:ENOV - Get Free Report) is expected to be announcing its Q2 2025 earnings results before the market opens on Thursday, August 7th. Analysts expect the company to announce earnings of $0.74 per share and revenue of $555.80 million for the quarter. Enovis has set its FY 2025 guidance at 2.950-3.100 EPS.

Enovis (NYSE:ENOV - Get Free Report) last announced its quarterly earnings data on Thursday, May 8th. The company reported $0.81 EPS for the quarter, topping analysts' consensus estimates of $0.74 by $0.07. The firm had revenue of $558.83 million for the quarter, compared to the consensus estimate of $558.80 million. Enovis had a positive return on equity of 5.99% and a negative net margin of 37.65%. The firm's revenue was up 8.2% compared to the same quarter last year. During the same quarter last year, the business posted $0.50 earnings per share. On average, analysts expect Enovis to post $3 EPS for the current fiscal year and $3 EPS for the next fiscal year.

Enovis Trading Down 4.0%

NYSE:ENOV traded down $1.06 during trading hours on Friday, hitting $25.74. The company had a trading volume of 1,336,017 shares, compared to its average volume of 1,197,382. The company has a current ratio of 2.55, a quick ratio of 1.32 and a debt-to-equity ratio of 0.52. The company has a 50-day moving average of $31.27 and a 200 day moving average of $36.24. The company has a market cap of $1.47 billion, a P/E ratio of -1.85 and a beta of 1.70. Enovis has a 1 year low of $25.70 and a 1 year high of $49.83.

Institutional Investors Weigh In On Enovis

A number of institutional investors and hedge funds have recently added to or reduced their stakes in ENOV. Goldman Sachs Group Inc. lifted its stake in Enovis by 37.6% during the 1st quarter. Goldman Sachs Group Inc. now owns 267,617 shares of the company's stock worth $10,226,000 after acquiring an additional 73,116 shares in the last quarter. AQR Capital Management LLC lifted its stake in Enovis by 12.5% during the 1st quarter. AQR Capital Management LLC now owns 63,671 shares of the company's stock worth $2,363,000 after acquiring an additional 7,072 shares in the last quarter. Finally, Empowered Funds LLC lifted its stake in Enovis by 13.0% during the 1st quarter. Empowered Funds LLC now owns 6,515 shares of the company's stock worth $249,000 after acquiring an additional 749 shares in the last quarter. Hedge funds and other institutional investors own 98.45% of the company's stock.

Analyst Upgrades and Downgrades

Several analysts have issued reports on the company. Canaccord Genuity Group dropped their target price on Enovis from $75.00 to $70.00 and set a "buy" rating for the company in a report on Wednesday, May 14th. Needham & Company LLC dropped their target price on Enovis from $64.00 to $57.00 and set a "buy" rating for the company in a report on Friday, May 9th. Evercore ISI dropped their target price on Enovis from $48.00 to $46.00 and set an "outperform" rating for the company in a report on Tuesday, July 8th. Finally, JMP Securities dropped their target price on Enovis from $62.00 to $55.00 and set a "market outperform" rating for the company in a report on Friday, May 9th. One investment analyst has rated the stock with a hold rating and four have given a buy rating to the company. According to MarketBeat, the company presently has an average rating of "Moderate Buy" and an average price target of $55.60.

Enovis Company Profile

Enovis Corporation operates as a medical technology company focus on developing clinically differentiated solutions worldwide. It also manufactures and distributes medical devices which are used for reconstructive surgery, rehabilitation, pain management, and physical therapy. The company operates through Prevention and Recovery, and Reconstructive segments.